The bispecific anti-CD3 x anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer

摘要

Expression of CD155 differs between tumor and normal tissues, and high expression of this molecule can promote tumor metastasis. Here, we investigate whether CD155 can serve as a target for T cell-mediated immunotherapy of human prostate cancer. We first demonstrate that prostate cancer cells, including PC-3, PC-3 M, and LNCAP cells, express CD 155 at high levels. Next, the specific cytotoxic activity of activated T cells (ATCs) armed with a novel anti-CD3 x anti-CD 155 bispecific antibody (CD155Bi-Ab) against tumor cells was evaluated by flow cytometry, lactate dehydrogenase assay (LDH), and ELISA. In contrast to unarmed ATCs, an increase in the cytotoxic activity of CD 155Bi-armed ATCs against tumor cells was observed at an effector/ target (E/T) ratio of 5:1. Moreover, CD 155Bi-armed ATCs secreted more IFN-γ, TNF-a, and IL-2 and expressed higher levels of the activation marker CD69 than did unarmed ATCs. As CD 155 Bi-Ab enhances the ability of ATCs to kill prostate cancer cells, CD 155 is an effective target for cytotoxic T cells in human prostate cancer therapy.